Ocugen, Inc.

OCGN

NASDAQHealthcareBiotechnology

在 GoAI 中打開

收盤時

US$1.36

−US$0.03 · -2.16%

8月24日下午4:00 ET

盤後

US$1.3693

+US$0.0093 · +0.68%

8月24日下午4:49 ET

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

33/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

動能

Weakening

情緒

Mixed

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Shankar Musunuri
上市以來: 2014年12月3日
僱員: 116

市場位置

日內區間

目前US$1.36，

US$1.33US$1.36

52週區間

目前US$1.36，

US$1.00US$2.725

開盤價: US$1.36
前收盤價: US$1.39
成交量: 0; 0× 平均值
平均成交量: 676.65萬; 日均成交量
市值: 4.61億 USD
貝塔: 2.2; 市場參考 1
50天平均值: US$1.3509; 高於平均水平+0.67%
200天平均值: US$1.5086; 低於平均水平-9.85%

財務數據

財務快照

估值與收益率

企業價值: 4.2億 USD
本益比（TTM）: -5.39×
股價淨值比（TTM）: -27.82×
股價營收比（TTM）: 100.7×
EV/EBITDA: -6.97×
盈餘收益率: -16.74%
自由現金流收益率: -14.10%
股息率: 0.00%

獲利能力和效率

毛利率: 100.00%
營業利益率: -1504.43%
淨利潤率: -1786.27%
股東權益報酬率: 557.67%
資產報酬率: -155.91%
投入資本報酬率: -278.62%

財務健康

負債權益比: -5.31×
流動比率: 1.06×
奧特曼 Z 分數: -5.24
皮奧特羅斯基 F 分數: 2 共 9 個

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$5.00

上漲空間 267.65%

過去 12 個月12個月預測最高：US$6.00平均的：US$5.00最低：US$3.50

評級分佈

6項評級

強力買進00%

買進583%

持有117%

賣出00%

強力賣出00%

OCGN 訊息

defenseworld.net2026年8月17日

Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50

Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research…

閱讀原始碼

marketbeat.com2026年8月15日

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa,…

閱讀原始碼

zacks.com2026年8月7日

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

閱讀原始碼

marketbeat.com2026年8月7日

Ocugen Q2 Earnings Call Highlights

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the…

閱讀原始碼

seekingalpha.com2026年8月6日

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

閱讀原始碼

zacks.com2026年8月6日

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.

閱讀原始碼